You just read:

CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C (NPC) Conducted by Arimoclomol Licensee Orphazyme A/S

News provided by

CytRx Corporation

Feb 06, 2019, 09:00 ET